UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer

Clinical cancer research, 2014-12, Vol.20 (24), p.6504-6516

2014

Link zum Volltext

Verfügbarkeit prüfen

733 Phase 1 study of ultra-high concentration nitric oxide ablation in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A827-A827

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2096: Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2096-2096

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2205: CBT-102, an oral small molecule multi-kinase inhibitor, demonstrates favorable CSF-1R activity, offering means of controlling tumor associated macrophages

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2205-2205

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3945: CBT-102, an oral multi-kinase small molecule, demonstrates favorable activity in human hepatocellular carcinoma animal models and cardiac safety in rabbit Purkinje and beagle dogs compared to sorafenib

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3945-3945

2018

Link zum Volltext

Verfügbarkeit prüfen

Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.108-108

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15125-e15125

2020

Link zum Volltext

Verfügbarkeit prüfen

An observational study evaluating the expression of HER2 (1+, 2+, and 3+) with HLA A2/A3+ in gastric adenocarcinoma patients

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.18-18

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of novel peptide vaccines on secondary recurrences and survivorship

Journal of clinical oncology, 2016-01, Vol.34 (3_suppl), p.e274-e274

2016

Link zum Volltext

Verfügbarkeit prüfen

The Benefits of In-Home Pharmacy Evaluation for Older Persons

Journal of the American Geriatrics Society (JAGS), 1997-02, Vol.45 (2), p.211-214

1997

Link zum Volltext

Verfügbarkeit prüfen

Analytical validation of Bond Oracle HER2 IHC system for identifying low to intermediate HER2-expressing breast cancer in NeuVax PRESENT phase III clinical trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e11609-e11609

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3435: GTB-5550 (cam16-IL15-camB7H3) trispecific killer engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3435-3435

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract A200: CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A200-A200

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors

Cancer chemotherapy and pharmacology, 2014-07, Vol.74 (1), p.195-204

2014

Link zum Volltext

Verfügbarkeit prüfen

Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients

Hepatology (Baltimore, Md.), 2003-12, Vol.38 (6), p.1419-1427, Article ajhep09040

2003

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2317: SGI-110 alters ovarian cancer stem cells to prevent recurrent and chemoresistant ovarian cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2317-2317

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2013-02, Vol.71 (2), p.463-471

2013

Link zum Volltext

Verfügbarkeit prüfen

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Blood, 2015-12, Vol.126 (23), p.4074-4074

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-15-02: HER2 discordant results in local vs. central testing in the phase 3 nelipepimut-S trial and implementation of Leica Bond Oracle HER2 Immunohistochemistry (IHC) System for low and intermediate levels (1+, 2+) of HER2 protein expression as a companion diagn

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P2-P2-15-02

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting PIM kinase activity significantly augments the efficacy of cytarabine

British journal of haematology, 2012-01, Vol.156 (1), p.129-132

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA17: Targeting the methylome for epigenetic resensitization of ovarian cancer

Clinical cancer research, 2013-10, Vol.19 (19_Supplement), p.IA17-IA17

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA)

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2320-2320

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4077: Chemosensitizing effects of the novel, small molecule DNA methylation inhibitor SGI-110 in ovarian cancer

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.4077-4077

2012

Link zum Volltext

Verfügbarkeit prüfen

Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST)

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.105-105

2013

Link zum Volltext

Verfügbarkeit prüfen

First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7030-7030

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(62)
Berichte
(2)

Sprache

Englisch
(64)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer

733 Phase 1 study of ultra-high concentration nitric oxide ablation in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies

Abstract 2096: Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models

Abstract 2205: CBT-102, an oral small molecule multi-kinase inhibitor, demonstrates favorable CSF-1R activity, offering means of controlling tumor associated macrophages

Abstract 3945: CBT-102, an oral multi-kinase small molecule, demonstrates favorable activity in human hepatocellular carcinoma animal models and cardiac safety in rabbit Purkinje and beagle dogs compared to sorafenib

Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma

A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors

An observational study evaluating the expression of HER2 (1+, 2+, and 3+) with HLA A2/A3+ in gastric adenocarcinoma patients

Effect of novel peptide vaccines on secondary recurrences and survivorship

The Benefits of In-Home Pharmacy Evaluation for Older Persons

Analytical validation of Bond Oracle HER2 IHC system for identifying low to intermediate HER2-expressing breast cancer in NeuVax PRESENT phase III clinical trial

Abstract 3435: GTB-5550 (cam16-IL15-camB7H3) trispecific killer engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas

Abstract A200: CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models

Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors

Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients

Abstract 2317: SGI-110 alters ovarian cancer stem cells to prevent recurrent and chemoresistant ovarian cancer

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Abstract P2-15-02: HER2 discordant results in local vs. central testing in the phase 3 nelipepimut-S trial and implementation of Leica Bond Oracle HER2 Immunohistochemistry (IHC) System for low and intermediate levels (1+, 2+) of HER2 protein expression as a companion diagn

Targeting PIM kinase activity significantly augments the efficacy of cytarabine

Abstract IA17: Targeting the methylome for epigenetic resensitization of ovarian cancer

Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA)

Abstract 4077: Chemosensitizing effects of the novel, small molecule DNA methylation inhibitor SGI-110 in ovarian cancer

Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST)

First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML)

Suchergebnisse filtern